Prolonged bisphosphonate use may be associated with an increased risk of low-energy femur fractures in older women.
Prolonged bisphosphonate use may be associated with an increased risk of low-energy femur fractures in older women, according to a letter to the editor published in a recent issue of the New England Journal of Medicine.
Brett A. Lenart, of Weill Cornell Medical College in New York City, and two colleagues describe 15 cases of atypical, low-energy femur fractures occurring in postmenopausal women who had been taking alendronate for a mean of 5.4 years. Low-energy fractures were defined as those resulting from a fall from standing height or less.
All patients had subtrochanteric or proximal diaphyseal femur fractures, a relatively rare type of osteoporotic hip fracture, the authors note. Ten of the patients exhibited a distinct radiographic pattern of a simple fracture with beaking of the cortex and diffuse cortical thickening of the proximal femoral shaft. Mean duration of alendronate use was longer in these 10 patients compared to the five without this pattern (7.3 years vs. 2.8 years).
Lenart BA, Lorich DG, Lane JM, et al. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358:1304-1306.
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More